Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy.

Fuente: PubMed
Salvato in:
Dettagli Bibliografici
Autori principali: Selvaraj, Chandrabose, Desai, Deepali, Santos-Villalobos, Sergio de Los, Jayaprakashvel, Mani, Muthezhilan, Radhakrishnan, Singh, Sanjeev Kumar
Natura: Artículo científico
Lingua:en
Pubblicazione: Advances in protein chemistry and structural biology 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1868266095172911106
author Selvaraj, Chandrabose
Desai, Deepali
Santos-Villalobos, Sergio de Los
Jayaprakashvel, Mani
Muthezhilan, Radhakrishnan
Singh, Sanjeev Kumar
author_facet Selvaraj, Chandrabose
Desai, Deepali
Santos-Villalobos, Sergio de Los
Jayaprakashvel, Mani
Muthezhilan, Radhakrishnan
Singh, Sanjeev Kumar
Selvaraj, Chandrabose
Desai, Deepali
Santos-Villalobos, Sergio de Los
Jayaprakashvel, Mani
Muthezhilan, Radhakrishnan
Singh, Sanjeev Kumar
collection PubMed - marine biology
contents Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy. Selvaraj, Chandrabose Desai, Deepali Santos-Villalobos, Sergio de Los Jayaprakashvel, Mani Muthezhilan, Radhakrishnan Singh, Sanjeev Kumar Antimicrobial Peptides Biotechnology Aquatic Organisms Animals Humans The global antimicrobial resistance (AMR) crisis drives the demand for novel therapeutics, positioning marine-derived antimicrobial peptides (AMPs) as sustainable alternatives with unique structural and functional advantages. These cationic, amphipathic molecules, from the source of diverse marine organisms, such as invertebrates, extremophiles, and cyanobacteria, exhibit broad-spectrum activity against drug-resistant pathogens through mechanisms like membrane disruption and immunomodulation. Their low resistance propensity and multifunctional bioactivity (eg., antioxidant, antimicrobial, anticancer) underscore therapeutic potential beyond the conventional antibiotics. Advances in genomic and metagenomic tools, machine learning, and synthetic biology are revolutionizing AMP discovery, enabling targeted mining of marine biodiversity and peptide optimization for enhanced stability and specificity. Biotechnological innovations support scalable production through heterologous expression and marine biomass valorization, which aligns with the principles of the circular economy. Marine-sourced AMPs demonstrate transformative applications across various healthcare, aquaculture, food safety, and environmental remediation, that majorly reduce the dependence on synthetic chemicals. Their integration into blue bioeconomy frameworks is promoting sustainable bio-prospects, marine ecosystem conservation, and progress towards the United Nations Sustainable Development Goals. This review narrates the collective research and also addresses the critical challenges, including production scalability and regulatory frameworks, to outline a clear pathway for the marine sourced AMP commercialization. By bridging the antimicrobial innovation with circular biotechnology, marine-sourced AMPs are exemplifying the ocean's role as a reservoir of sustainable solutions for global health and bioeconomic resilience.
format Artículo científico
id pubmed_41581932
institution PubMed
language en
publishDate 2026
publisher Advances in protein chemistry and structural biology
record_format pubmed
spellingShingle Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy.
Selvaraj, Chandrabose
Desai, Deepali
Santos-Villalobos, Sergio de Los
Jayaprakashvel, Mani
Muthezhilan, Radhakrishnan
Singh, Sanjeev Kumar
Antimicrobial Peptides
Biotechnology
Aquatic Organisms
Animals
Humans
Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy. Selvaraj, Chandrabose Desai, Deepali Santos-Villalobos, Sergio de Los Jayaprakashvel, Mani Muthezhilan, Radhakrishnan Singh, Sanjeev Kumar Antimicrobial Peptides Biotechnology Aquatic Organisms Animals Humans The global antimicrobial resistance (AMR) crisis drives the demand for novel therapeutics, positioning marine-derived antimicrobial peptides (AMPs) as sustainable alternatives with unique structural and functional advantages. These cationic, amphipathic molecules, from the source of diverse marine organisms, such as invertebrates, extremophiles, and cyanobacteria, exhibit broad-spectrum activity against drug-resistant pathogens through mechanisms like membrane disruption and immunomodulation. Their low resistance propensity and multifunctional bioactivity (eg., antioxidant, antimicrobial, anticancer) underscore therapeutic potential beyond the conventional antibiotics. Advances in genomic and metagenomic tools, machine learning, and synthetic biology are revolutionizing AMP discovery, enabling targeted mining of marine biodiversity and peptide optimization for enhanced stability and specificity. Biotechnological innovations support scalable production through heterologous expression and marine biomass valorization, which aligns with the principles of the circular economy. Marine-sourced AMPs demonstrate transformative applications across various healthcare, aquaculture, food safety, and environmental remediation, that majorly reduce the dependence on synthetic chemicals. Their integration into blue bioeconomy frameworks is promoting sustainable bio-prospects, marine ecosystem conservation, and progress towards the United Nations Sustainable Development Goals. This review narrates the collective research and also addresses the critical challenges, including production scalability and regulatory frameworks, to outline a clear pathway for the marine sourced AMP commercialization. By bridging the antimicrobial innovation with circular biotechnology, marine-sourced AMPs are exemplifying the ocean's role as a reservoir of sustainable solutions for global health and bioeconomic resilience.
title Marine-derived antimicrobial peptides (AMPs): Blue biotechnological assets for sustainable healthcare and circular bioeconomy.
topic Antimicrobial Peptides
Biotechnology
Aquatic Organisms
Animals
Humans
url https://pubmed.ncbi.nlm.nih.gov/41581932/